163 related articles for article (PubMed ID: 37003083)
1. Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy.
Villacampa G; Cresta Morgado P; Navarro V; Viaplana C; Dienstmann R
Cancer Treat Rev; 2023 May; 116():102542. PubMed ID: 37003083
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Brito ABC; Camandaroba MPG; de Lima VCC
Thorac Cancer; 2021 Apr; 12(7):1058-1066. PubMed ID: 33586297
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?
Zhao Y; Mei T; Na F; Tian X; Ao R; Long X; Luo Q; Duan P; Zhu J; Wang Y; Huang M; Liu Y; Gong Y
Invest New Drugs; 2024 Apr; 42(2):196-206. PubMed ID: 38386170
[TBL] [Abstract][Full Text] [Related]
7. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
8. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis.
Villacampa G; Tolosa P; Salvador F; Sánchez-Bayona R; Villanueva L; Dienstmann R; Ciruelos E; Pascual T
Cancer Treat Rev; 2022 Mar; 104():102352. PubMed ID: 35144055
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis.
Wang Y; Han H; Zhang F; Lv T; Zhan P; Ye M; Song Y; Liu H
Br J Cancer; 2022 Sep; 127(5):948-956. PubMed ID: 35641819
[TBL] [Abstract][Full Text] [Related]
10. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.
Khan M; Du K; Ai M; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Yuan Y; Tian Y
Front Immunol; 2023; 14():1060308. PubMed ID: 36949944
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
[TBL] [Abstract][Full Text] [Related]
13. Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
García-Corbacho J; Indacochea A; González Navarro AE; Victoria I; Moreno D; Pesántez D; Angelats L; Modrego-Sanchez A; Sanfeliu E; Castillo O; Blasco P; Mezquita L; Viñolas N; Nogué M; Galván P; Adamo B; Basté N; Sauri T; Juan M; Prat A; Schettini F
Cancer Immunol Immunother; 2023 Jun; 72(6):1709-1723. PubMed ID: 36625938
[TBL] [Abstract][Full Text] [Related]
14. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
Ye J; Ji X; Dennis PA; Abdullah H; Mukhopadhyay P
Clin Pharmacol Ther; 2020 Dec; 108(6):1274-1288. PubMed ID: 32564368
[TBL] [Abstract][Full Text] [Related]
15. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis.
Zhu GL; Yang KB; Tang SQ; Peng L
Cancer Med; 2021 Dec; 10(23):8272-8287. PubMed ID: 34668660
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.
Boudou-Rouquette P; Arrondeau J; Gervais C; Durand JP; Fabre E; De Percin S; Villeminey CV; Piketty AC; Rassy N; Ulmann G; Damotte D; Mansuet-Lupo A; Giraud F; Alifano M; Wislez M; Alexandre J; Jouinot A; Goldwasser F
EBioMedicine; 2021 Nov; 73():103630. PubMed ID: 34688030
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
Shao T; Zhao M; Liang L; Tang W
Front Immunol; 2022; 13():948597. PubMed ID: 36389713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
